Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
The Path towards Effective Vaccines for Chronic Viral Infections
share announcement

The Path towards Effective Vaccines for Chronic Viral Infections

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 3739

Special Issue Editor

Dr. Peter Johannes Holst

E-Mail Website
Guest Editor
1. InProTher ApS, 2200 Copenhagen, Denmark
2. Faculty of Health and Medical Sciences, University of Copenhagen, 1165 Copenhagen, Denmark
Interests: experimental vaccines; immunotherapy; chronic viral infections; cancer; immunology

Special Issue Information

Dear Colleagues,

I am pleased to announce the launch of this Special Isuue of Vaccines titled “The Path Towards Effective Vaccines for Chronic Viral Infections”. We aim to publish a collection of papers related to the development of vaccines for chronic infections including manuscripts fouced on the essential basic immunology of chronic viral infections, novel vaccine technologies as used in experimental and clinical trials, and specific approaches being pursued against globally prominent infections. Authors are invited to submit relevant original research papers, short communications, reviews, and perspectives for consideration for inclusion.

Dr. Peter Johannes Holst
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Experimental Vaccines
  • Immunotherapy
  • Chronic infections
  • T cell vaccines
  • Neutralizing antibodies
  • non-neutralizing antibodies
  • Acute Infections
  • Progressive Infections
  • Latency

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

17 pages, 1694 KiB  
Article
Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge
by Xinle Cui, Zhouhong Cao, Yuriko Ishikawa, Sara Cui, Ken-Ichi Imadome and Clifford M. Snapper
Vaccines 2021, 9(3), 285; https://doi.org/10.3390/vaccines9030285 - 19 Mar 2021
Cited by 15 | Viewed by 3412
Abstract
Epstein–Barr virus (EBV) is the primary cause of infectious mononucleosis and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. EBV core fusion machinery envelope proteins gH/gL and gB coordinately mediate EBV fusion and entry into its target cells, B [...] Read more.
Epstein–Barr virus (EBV) is the primary cause of infectious mononucleosis and is strongly implicated in the etiology of multiple lymphoid and epithelial cancers. EBV core fusion machinery envelope proteins gH/gL and gB coordinately mediate EBV fusion and entry into its target cells, B lymphocytes and epithelial cells, suggesting these proteins could induce antibodies that prevent EBV infection. We previously reported that the immunization of rabbits with recombinant EBV gH/gL or trimeric gB each induced markedly higher serum EBV-neutralizing titers for B lymphocytes than that of the leading EBV vaccine candidate gp350. In this study, we demonstrated that immunization of rabbits with EBV core fusion machinery proteins induced high titer EBV neutralizing antibodies for both B lymphocytes and epithelial cells, and EBV gH/gL in combination with EBV trimeric gB elicited strong synergistic EBV neutralizing activities. Furthermore, the immune sera from rabbits immunized with EBV gH/gL or trimeric gB demonstrated strong passive immune protection of humanized mice from lethal dose EBV challenge, partially or completely prevented death respectively, and markedly decreased the EBV load in peripheral blood of humanized mice. These data strongly suggest the combination of EBV core fusion machinery envelope proteins gH/gL and trimeric gB is a promising EBV prophylactic vaccine. Full article
(This article belongs to the Special Issue The Path towards Effective Vaccines for Chronic Viral Infections)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop